Show simple item record

dc.contributor.authorBarrios Diaz, Monica Daniela
dc.contributor.authorRojas López, Kristian Kamilo
dc.contributor.authorPinilla-Roncancio, Mónica
dc.coverage.spatialBogota, Colombiaes_CO
dc.description.abstractABSTRACT Introduction: Atopic dermatitis (AD) is a chronic, remitting-relapsing, and inflammatory dermatosis. It occurs in patients of all ages, with a peak in children and young adults. Immunomodulator treatment improves the quality of life by reducing the intensity and frequency of symptomatic periods, number of physician visits, and cost of the treatment for patients and the health system. Methodology: A cost-effectiveness analysis, comparing tacrolimus and hydrocortisone butyrate 1% to treat an acute flare of moderate to severe AD in Colombia for patients aged two years or older. A decision tree model was designed in this analysis, and we used a health system perspective and evaluated only direct costs, during 2019. Results: The treatment of a symptomatic exacerbation episode of moderate to severe AD is cost-effective with tacrolimus compared to hydrocortisone. Discussion: tacrolimus is dominant and can be cost-saving because its use reduces complications and adverse events that increase treatment costs. Conclusion: The use of tacrolimus will benefit both patients and the health care system.es_CO
dc.sourceinstname:Universidad de los Andeses_CO
dc.sourcereponame:Repositorio Institucional Sénecaes_CO
dc.titleEconomic evaluation of Tacrolimus and Hydrocortisone in acute flare of atopic dermatitises_CO
dc.typeArtículo de revistaes_CO
dc.subject.keywordAtopic Dermatitises_CO
dc.subject.keywordCost-effectiveness Analysises_CO
dc.subject.keywordAcute Flarees_CO

Files in this item


This item appears in the following Collection(s)

  • Documentos de trabajo [40]
    Los documentos de trabajo son documentos preliminares de carácter técnico o científico.

Show simple item record